1MOGG R, MEHROTRA D V. Analysis of antiretroviral immunotherapy trials with potentially non-normal and incomplete longitudinal data[J]. Stat Med, 2007, 26 (3) : 484-497. 被引量：1
2GAHERY H, DANIEL N, CHARMETEAU B, et al. New CD4 ^+ and CD8 ^+ T cell responses induced in chronically HIV type-1 -infected patients after immunizations with an HIV type 1 lipopeptide vaccine[J], AIDS Res Hum Retroviruses, 2006, 22 (7) : 684- 694. 被引量：1
3LORI F, CALAROTA S A, LISZIEWICZ J. Nanochemistry-based immunotherapy for HIV-1 [ J ] . Curr Med Chem, 2007, 14 (18): 1911-1919. 被引量：1
4HARDY G A, IMAMI N, NELSON M R, et al. A phase Ⅰ , randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy [ J ]. J Immune Based Ther Vaccines, 2007, 11 (5): 6. 被引量：1
5KILBY J M, BUCY R P, MILDVAN D, et al. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interlcukin-2 cycles to promote efficient control of viral replication ( ACTG A5024 ) [J]. J Infect Dis, 2006, 194 (12): 1672-1676. 被引量：1
9Centers for Diseases Control and Prevention. Sexually transmitted disease surveillanee2003[R]. Atlanta(GA): US Department of Health and Human Service, 2003: 15-36. 被引量：1
10Chen Jing-feng, Cai Wei-ping. Research progress of HIV/AIDS combined with tuberculosis[J]. Infectious disease information, 2008, 21(6): 332-334. 被引量：1
